ORAGENICS INC
OGEN · XNYSCIK 1174940fmd_01QV26V69CSB7H7JJSK3ABHTQE制造业 · 医药制剂模板: 标准
覆盖范围: 2010年1月01日 至 2026年9月30日，共 66 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | 0 | – | – | – | 0 | 0 | 0 | – | – |
| 营业成本 | 0 | 0 | – | – | – | – | – | – | – | – |
| 毛利润 | 0 | 0 | – | – | – | – | – | – | – | – |
| 研发费用 | 5 | 4 | 6 | 12 | 22 | 11 | 10 | 15 | 4 | 2 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | – | – | – |
| 营业费用合计 | 9 | 7 | 10 | 16 | 27 | 16 | 15 | 21 | 11 | 9 |
| 营业利润 | (9) | (7) | (10) | (16) | (27) | (16) | (14) | (21) | (11) | (9) |
| 利息费用 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 利息及投资收益 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 其他营业外收入（支出） | 0 | (0) | 0 | 0 | 0 | 0 | 0 | 0 | (0) | (1) |
| 税前利润 | (8) | (7) | (10) | (16) | (26) | (16) | (14) | (21) | (11) | (10) |
| 所得税费用 | 0 | 0 | 0 | – | – | – | – | – | – | (0) |
| 持续经营净利润 | (8) | (7) | (10) | – | – | – | – | – | – | (10) |
| 净利润 | (7) | (7) | (10) | (16) | (26) | (16) | (14) | (21) | (11) | (10) |
| 归属于普通股股东的净利润 | – | (7) | (11) | (16) | – | – | – | – | – | – |